Breaking the Silence

Quin Wills on ending liver disease as a silent killer.

“The scale of Ochre's work is uniquely powered to address the complexities of liver disease.”
Scott Friedman, MDChief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease."
Joel Dudley, PhDCSO of Tempus Labs; Associate Professor
of Genetics & Genomic Sciences
"Ochre changes the game for patients and greatly advances the field of liver disease."
Melissa Palmer, MDRenowned Hepatologist (KOL) and biopharma executive;
First to publish link between weight loss and NASH
cellular senescence
macroautophagy
beta oxidation
de novo lipogenesis
ER stress
intrinsic apoptosis
glucose metabolism
“The scale of Ochre's work is uniquely powered to address the complexities of liver disease.”
Scott Friedman, MDChief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease."
Joel Dudley, PhDAssociate Professor of Genetics and Genomic Sciences CSO, Tempus Labs
"Ochre changes the game for patients and greatly advances the field of liver disease."
Melissa Palmer, MDLeading hepatologist. First to publish link between weight loss and NASH

WHAT

At Ochre Bio, we’re developing therapies for the biggest liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. We're obsessive about...

Deep phenotyping livers at scale…

WATCH VIDEO

And designing precision RNA therapies to reprogram them…

WATCH VIDEO

To regenerate human livers outside the body.

WATCH VIDEO

WHY

Chronic liver disease is the only top ten global killer on the rise

"Liver disease is the third leading cause of premature death." UK Health Security Agency, July 2021

Without effective therapies, the only resort for many patients remains a liver transplant. However the supply of healthy donor organs cannot meet what’s required, with minorities disproportionately disadvantaged. 

Jack O’Meara on how improving outcomes for liver transplant patients is a first step towards treating chronic liver disease 

European Health for All database.  Data missing in 2000.

WHO

Built on decades of leading genomics and drug development experience, Ochre’s scientific teams are committed to making healthy livers available for patients everywhere.

We named Ochre Bio in honour of Nobel laureate, Sydney Brenner, for his remarkable scientific creativity. He passed away in 2019, the year Ochre was founded. We are a team who live by Clarke’s, Murphy’s, and Wheaton’s laws.

MORE

News & Announcements

VIEW ALL
VIEW ALL

Think you’d like to join our team?

Check out our open positions or ask us to hold your CV at jobs@ochre-bio.com

Subscribe for Updates

More
Careers
News
Contact
Locations
Oxford, UK
Taipei City, Taiwan
New York, NY
Contact
contact@ochre-bio.com

Subscribe for Updates

Twitter Linkedin-in

© 2022 Ochre Bio

Join our Mailing List

This website uses cookies to ensure you get the best experience on our website. View our policy here.

got it
Facebook-f Twitter